TCGA-NC-A5HF-01A-11R-A26W-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.210
- KRAS_SIGNALING_DN+0.190
- DNA_REPAIR+0.180
- HYPOXIA+0.170
- CHOLESTEROL_HOMEOSTASIS+0.150
- HEDGEHOG_SIGNALING+0.140
- SPERMATOGENESIS+0.120
- P53_PATHWAY+0.110
- GLYCOLYSIS+0.090
- MITOTIC_SPINDLE+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.610
- ALLOGRAFT_REJECTION-0.570
- INTERFERON_GAMMA_RESPONSE-0.550
- INFLAMMATORY_RESPONSE-0.450
- IL6_JAK_STAT3_SIGNALING-0.430
- KRAS_SIGNALING_UP-0.350
- COMPLEMENT-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- OXIDATIVE_PHOSPHORYLATION-0.280
- IL2_STAT5_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02163 | — | cohortSQ2 | 0.868 |
| 2 | TCGA-85-8479-01A-11R-2326-07 | — | cohortSQ1 | 0.860 |
| 3 | MNG1255 | — | — | 0.834 |
| 4 | TCGA-56-A4BX-01A-11R-A24H-07 | — | cohortSQ2 | 0.829 |
| 5 | SRR1403875 | GTEX | — | 0.821 |
| 6 | SRR6013546 | — | cohortA1 | 0.815 |
| 7 | 67da6843-b0fe-4ff9-8cef-a66e606c8f54 | — | — | 0.806 |
| 8 | SRR8518307 | — | D | 0.803 |
| 9 | MDT-AP-0350 | Med | Medulloblastoma | 0.802 |
| 10 | 20040095.TNBC | — | E | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.050 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.010 | Idelalisib | — uncovered |